Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00008)
| Name |
Central nervous system cancer
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2A02
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Target for Ferroptosis | Marker/Suppressor | |||
| Responsed Disease | CNS diseases [ICD-11: 2A02] | |||
| Responsed Drug | Polygonatum cyrtonemaHua Polysaccharides | Investigative | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| In Vitro Model | BV-2 cells | Normal | Mus musculus | CVCL_0182 |
| Response regulation | Subsequent studies have revealed that Polygonatum cyrtonemaHua Polysaccharides (PCP) alleviates ferroptosis in microglia due to protein levels of ERASTIN/RSL3 inhibitor SLC7A11/GPX4 by activating the NRF2/HO-1 signaling pathway. PCP has the development potential as a new drug candidate for treating CNS diseases. | |||
Heme oxygenase 1 (HMOX1)
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | CNS diseases [ICD-11: 2A02] | |||
| Responsed Drug | Polygonatum cyrtonemaHua Polysaccharides | Investigative | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| In Vitro Model | BV-2 cells | Normal | Mus musculus | CVCL_0182 |
| Response regulation | Subsequent studies have revealed that Polygonatum cyrtonemaHua Polysaccharides (PCP) alleviates ferroptosis in microglia due to protein levels of ERASTIN/RSL3 inhibitor SLC7A11/GPX4 by activating the NRF2/HO-1 signaling pathway. PCP has the development potential as a new drug candidate for treating CNS diseases. | |||
